Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH2 | P40926 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | HAT1 | O14929 | 1/20 | 0.58 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714028 | 0.91 | MDH2 (0.85) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL6764594 | 0.90 | MAOB (0.61) | MDH2ALDH1A1HPGDSMN1; SMN2MAOB | |
| SCHEMBL28106376 | 0.88 | MDH2 (0.69) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL2433763 | 0.88 | MDH2 (0.69) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL28757823 | 0.87 | MDH2 (0.72) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL6824330 | 0.86 | MDH2 (0.70) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL6823832 | 0.86 | MDH2 (0.70) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL2811774 | 0.85 | ALDH1A1 (0.66) | MDH2ALDH1A1HPGDSMN1; SMN2MAOB | |
| SCHEMBL2084401 | 0.85 | MDH2 (0.66) | MDH2ALDH1A1HPGDSMN1; SMN2IMPDH2 | |
| SCHEMBL6021884 | 0.85 | MDH2 (0.65) | MDH2ALDH1A1HPGDSMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2015130830-A9 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015130842-A9 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2015130845-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130830-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130830-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130842-A2 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | TFPI, CFD, C9 | MDH2 1934/4885ALDH1A1 2728/4885HPGD 3029/4885 |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | CFD, TFPI, F12 | MDH2 2530/4885ALDH1A1 3430/4885HPGD 1497/4885 |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | CFD, C9, CFH | MDH2 2692/4885ALDH1A1 2381/4885HPGD 3269/4885 |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | MDH2 1992/4885ALDH1A1 3727/4885HPGD 2701/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | MDH2 1934/4885ALDH1A1 2728/4885HPGD 3029/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | MDH2 1471/4885ALDH1A1 2385/4885HPGD 2340/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | MDH2 1940/4885ALDH1A1 3450/4885HPGD 3615/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | MDH2 1992/4885ALDH1A1 3727/4885HPGD 2701/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | MDH2 2692/4885ALDH1A1 2381/4885HPGD 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.